Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

If you own or are considering buying pharma laggards Pfizer ( PFE +1.42%), Bristol Myers Squibb ( BMY +0.26%), and Merck ( ...

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped ...

Pfizer is launching seven phase 3 studies for PF-4044 soon and plans to initiate an additional 10 (at least) by the end of ...

3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share ...

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two ...

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

With all that in mind, if you have $2,000 available to invest that isn't needed for monthly bills, to pay down short-term ...

The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...